ICU Medical Posts $1.07 Q3 EPS, Up Sharply From $0.76 Last Quarter
ICUI sits 48% above its 52-week low of $113.37 on elevated volume (2.1× avg).
Summary
ICU Medical reported third-quarter GAAP EPS of $1.07, a step up from the $0.76 it posted in Q2 2026, on net income of $26.8M and revenue of $560.4M. That prior quarter's profit was flattered by a one-time tariff refund that pushed gross margin to 42.6%, so holding above it suggests the underlying business mix is carrying more of the load. The company reaffirmed its fiscal year 2026 guidance and expects results at the high end of the range. The stock trades near $167.65 with a roughly $4.2 billion market value, so a clean beat on the bottom line is meaningful for a mid-cap medtech name.
At the time of this announcement, ICUI was trading at $167.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.2B. The 52-week trading range was $113.37 to $192.85. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.